I. Perevozskaya

发表

Adaptive Group-Sequential Multi-regional Outcome Studies in Vaccines

I. Perevozskaya, 2018 .

Advances in Statistical Approaches to Oncology Drug Development

Olga V. Marchenko, G. Rosner, A. Ivanova, 2014, Therapeutic innovation & regulatory science.

Bayesian Optimal Designs for Phase I Clinical Trials

L. Haines, W. Rosenberger, I. Perevozskaya, 2003, Biometrics.

Simulation Practices for Adaptive Trial Designs in Drug and Device Development

S. Leonov, A. Hartford, V. Dragalin, 2019, Statistics in Biopharmaceutical Research.

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans.

D. Connolly, J. Paolini, J. Wagner, 2008, Journal of clinical lipidology.

Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.

M. Farnier, I. Perevozskaya, B. Gil-Extremera, 2007, American heart journal.

Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients

A. Lewin, L. Meneghini, I. Perevozskaya, 2005, Diabetes, obesity & metabolism.

patient-oriented and epidemiological research VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate

M. Farnier, I. Perevozskaya, D. Kush, 2008 .

Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.

D. Tribble, B. Gumbiner, T. Musliner, 2008, Metabolism: clinical and experimental.

Discussion: “Bayesian enrichment strategies for randomized discontinuation trials”.

I. Perevozskaya, 2012, Biometrics.

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

M. Freeman, M. Davies, B. Gumbiner, 2005 .

1084-169 Efficacy and safety of ezetimibe coadministered with simvastatin versus simvastatin alone in thiazolidinedione-treated patients with type 2 diabetes mellitus

A. Lewin, L. Meneghini, I. Perevozskaya, 2004 .

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.

M. Freeman, B. Gumbiner, M. Farnier, 2005, European heart journal.

Optimal design for the proportional odds model

William F. Rosenberger, Linda M. Haines, Inna Perevozskaya, 2003 .

A Simulation Study to Compare New Adaptive Dose–Ranging Designs

Frank Bretz, Joshua R. Smith, José Pinheiro, 2010 .

Predicting the COVID-19 Pandemic Impact on Clinical Trial Recruitment

M. Zwierzyna, J. Euesden, Graeme Archer, 2021, Statistics in Biopharmaceutical Research.

Adaptive Dose-Response Studies

Paul Gallo, Brenda Gaydos, Michael Krams, 2006 .

Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans

D. Tribble, T. Sudhop, D. Lütjohann, 2002, Circulation.

Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies

Frank Bretz, Joshua R. Smith, Chyi-Hung Hsu, 2010 .

Adaptive dose finding based on t‐statistic for dose–response trials

Anastasia Ivanova, Inna Perevozskaya, A. Ivanova, 2008, Statistics in medicine.

Constrained Bayesian Optimal Designs for Phase I Clinical Trials: Continuous Dose Space

William F. Rosenberger, Linda M. Haines, Inna Perevozskaya, 2001 .

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

M. Kipnes, A. Lewin, L. Meneghini, 2004, Clinical therapeutics.

Abstract 190: A Niacin Receptor Partial Agonist, MK-0354, Robustly Reduces Plasma Free Fatty Acids and Produces Little Flushing but Fails to Alter LDL-C, HDL-C, and Triglycerides in Humans

D. Connolly, J. Paolini, J. Wagner, 2007 .